NCT03459170View on ClinicalTrials.gov

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 1, 2018

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2035

Conditions
Hematologic Malignancy
Interventions
BIOLOGICAL

BPX-501 T cells

Biological: T cells transduced with CaspaCIDe® safety switch

DRUG

rimiducid

administered to eliminate BPX-501 cells in the event of GVHD

Trial Locations (3)

10126

Ospedale Infantile Regina Margherita, Turin

27100

San Matteo Hospital, Pavia

00161

IRCCS Ospedale Pediatrico Bambino Gesù, Rome

Sponsors
All Listed Sponsors
lead

Bellicum Pharmaceuticals

INDUSTRY